Publications

1. Package advice on the lock procedure medicinal product olaparib (Lynparza®) for the treatment of hereditary breast cancer

   The National Health Care Institute has assessed whether the medicinal product olaparib (Lynparza®) can be reimbursed from the ...

   Report | 13-02-2024

2. Guideline for economic evaluations in healthcare (2024 version)

   More often considerations are being made about the cost-effectiveness of healthcare intervention what should be reimbursed from ...

   Report | 16-01-2024

3. Advice - Reimburse voclosporin (Lupkynis®) for the treatment of rare kidney inflammation (lupus nephritis)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse voclosporin ...

   Report | 21-12-2023

4. Advice - Adjustment of reimbursement conditions for lenacapavir (Sunlenca®)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to adjust the conditions of ...

   Report | 20-12-2023

5. Advice - Extension of reimbursement conditions for risdiplam (Evrysdi®)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to also reimburse risdiplam ...

   Report | 20-12-2023

6. Package advice on the lock procedure medicinal product abemaciclib (Verzenios®) for the treatment of breast cancer

   The National Health Care Institute has assessed whether the medicinal product abemaciclib (Verzenios®) can be reimbursed as an ...

   Report | 13-12-2023

7. GVS advice reassessment migalastat (Galafold®) for the treatment of Fabry disease

   At the request of the Minister for Health, Welfare and Sport (VWS), the National Health Care Institute assessed whether ...

   Report | 13-12-2023

8. Package advice for the lock procedure for evinacumab (Evkeeza®) for the treatment of a rare form of elevated cholesterol

   The National Health Care Institute has assessed whether the medicinal product evinacumab (Evkeeza®) can be reimbursed from the ...

   Report | 13-12-2023

9. GVS advice tezepelumab (Tezspire®) for the treatment of patients 12 years and older with severe asthma

   The National Health Care Institute has assessed whether tezepelumab (Tezspire®) can be included in the Medicine Reimbursement ...

   Report | 12-12-2023

10. Package advice for the lock procedure medicinal product ravulizumab (Ultomiris®) for the treatment of adult patients with myasthenia gravis

    The National Health Care Institute has assessed whether the medicinal product ravulizumab (Ultomiris®) can be reimbursed from the ...

    Report | 12-12-2023